Brokers Issue Forecasts for FBRX FY2026 Earnings

Forte Biosciences, Inc. (NASDAQ:FBRX) – Investment analysts at Brookline Capital Management issued their FY2026 earnings per share estimates for shares of Forte Biosciences in a research report issued on Thursday, November 14th. Brookline Capital Management analyst K. Raja expects that the company will post earnings per share of ($2.17) for the year. The consensus estimate for Forte Biosciences’ current full-year earnings is ($22.50) per share. Brookline Capital Management also issued estimates for Forte Biosciences’ FY2027 earnings at ($1.66) EPS and FY2028 earnings at ($1.42) EPS.

Separately, Chardan Capital upped their price target on shares of Forte Biosciences from $3.00 to $64.00 and gave the stock a “buy” rating in a research report on Friday.

Forte Biosciences Price Performance

Shares of NASDAQ FBRX opened at $6.11 on Monday. The firm has a market capitalization of $8.92 million, a PE ratio of -0.38 and a beta of 0.04. Forte Biosciences has a 1-year low of $4.11 and a 1-year high of $21.25. The business’s fifty day moving average price is $5.46 and its two-hundred day moving average price is $2.37.

Forte Biosciences Company Profile

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.